{"id":"arry-380-her2-inhibitor-oral","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARRY-380 is a monoclonal antibody that binds to the HER2 receptor, inhibiting its activity.","oneSentence":"HER2 inhibitor","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:54:43.240Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT00650572","phase":"PHASE1","title":"A Study of ARRY-380 in Patients With Advanced HER2+ Cancer","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2008-05","conditions":"Cancer","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ARRY-380, HER2 inhibitor; oral","genericName":"ARRY-380, HER2 inhibitor; oral","companyName":"Seagen Inc.","companyId":"seagen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HER2 inhibitor Used for Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}